ASL: A Promising Drug Target for Neurodegenerative Diseases (G435)

Target Name: ASL

NCBI ID: G435

Content of Review Report on ASL Target / Biomarker

ASL

ASL: A Promising Drug Target for Neurodegenerative Diseases

ASL (Argininosuccinase), also known as ASCS (Arginine Sulfur Convertase), is an enzyme involved in the metabolism of arginine, a crucial amino acid that plays a vital role in various cellular processes. Arginine is produced naturally in the body and is also obtained from dietary sources such as nuts, seeds, and legumes. However, when arginine levels become imbalanced or are unable to be produced efficiently, it can lead to a range of health issues including cardiovascular disease, neurodegenerative diseases, and certain cancers. As a result , ASL has emerged as a promising drug target and biomarker for the development of new treatments for these diseases.

ASL is a protein that consists of 116 amino acids and has a molecular weight of 13.9 kDa. It is found in various cell types, including red blood cells, white blood cells, and tissue cells. ASL is primarily localized to the endoplasmic reticulum (ER ) and is involved in the transmembrane delivery of arginine across the cell membrane. It does this by catalyzing the conversion of arginine to arginine Glycyl (AG) via a series of intermediate steps.

ASL functions as a critical enzyme in the production of arginine, which is a precursor to nitric oxide (NO), a well-known signaling molecule that plays a crucial role in cardiovascular health. Arginine is converted to AG by ASL in the ER, where it is then transported to the cytosol where it can be further metabolized by other enzymes. AG is also a key precursor to arginine hydroxylase (ASH), which is responsible for the production of arginine from aglycylated L-carnitine (ALCAR), a compound that is also produced by ASL in the ER.

ASL is a potent drug target due to its unique mechanism of action and its involvement in various diseases. Its ability to modulate arginine levels and its involvement in the production of arginine, as well as its location in the ER, make it an attractive target for small molecules and antibodies that can modulate its activity.

One of the key advantages of ASL as a drug target is its ability to cross-talk with multiple signaling pathways, including the production and degradation of nitric oxide, angiotensin-converting enzyme (ACE) signaling, and the production of carbonate groups, which are involved in cell signaling. This means that ASL has the potential to modulate the activity of multiple enzymes and contribute to the development of multimodal therapeutic approaches.

ASL has also been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial cells. ASL has been shown to play a role in the production of neurofibrillary tangles and neuroglial cells, as well as in the modulation of the production of reactive oxygen species (ROS) that can damage brain cells.

In addition to its involvement in neurodegenerative diseases, ASL has also been shown to contribute to the development and progression of cardiovascular disease. The production of arginine is a critical step in the production of nitric oxide, which is responsible for the regulation of blood flow and blood pressure. In addition, ASL has been shown to play a role in the modulation of angiotensin-converting enzyme (ACE) signaling, a key pathway involved in the regulation of blood pressure.

ASL has also been shown to contribute to the development and progression of certain cancers, including colon cancer. The production of arginine is a critical step in

Protein Name: Argininosuccinate Lyase

Functions: Catalyzes the reversible cleavage of L-argininosuccinate to fumarate and L-arginine, an intermediate step reaction in the urea cycle mostly providing for hepatic nitrogen detoxification into excretable urea as well as de novo L-arginine synthesis in nonhepatic tissues (PubMed:11747433, PubMed:11747432, PubMed:9045711, PubMed:22081021, PubMed:2263616). Essential regulator of intracellular and extracellular L-arginine pools. As part of citrulline-nitric oxide cycle, forms tissue-specific multiprotein complexes with argininosuccinate synthase ASS1, transport protein SLC7A1 and nitric oxide synthase NOS1, NOS2 or NOS3, allowing for cell-autonomous L-arginine synthesis while channeling extracellular L-arginine to nitric oxide synthesis pathway (PubMed:22081021)

The "ASL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets